Renal cell-type associated therapeutic effects of semaglutide in a mouse model of hypertension accelerated diabetic kidney disease
Background & Aim Obesity, hyperglycemia and hypertension are critical risk factors for development of diabetic kidney disease (DKD). While emerging evidence suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists improve cardiovascular and renal outcomes in type 2 diabetes patients, their mode…
Whole organ staining and 3D light sheet imaging for pharmacological research
Speaker Urmas Roostalu Urmas is department manager for 3D Imaging and work in his team is focused on high throughput sample preparation and microscopy of proteins, mRNAs, and pharmacological compounds in whole organs. He has PhD in molecular biology and…
Nephroprotective effects of semaglutide in a preclinical model of hypertensive diabetic kidney disease
In this webinar, Gubra’s experts on preclinical DKD models, Principal Scientists Mette Østergaard and Henrik Björk Hansen, will discuss the effects of semaglutide on renal functional, histological and gene expression markers of advanced DKD in the db/db UNx-ReninAAV mouse.
Lost in translation – how to improve the translatability of rodent models of diabetic kidney disease
Senior scientist Mette Viberg Østergaard introduces to the challenges of using current rodent models of diabetic kidney disease in drug discovery and development. Mette then presents an example of how translatability may be improved in a model of diabetic kidney disease in…
Integrative transcriptomic profiling of a mouse model of hypertension-accelerated diabetic kidney disease
Disease Models & Mechanisms 14(10): dmm049086, 2021
Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease
American Journal of Physiology-Renal Physiology 321(2):F149-F161, 2021